# CX-4945 in Viral Community Acquired Pneumonia

> **NCT06202521** · PHASE2 · TERMINATED · sponsor: **Senhwa Biosciences, Inc.** · enrollment: 45 (actual)

## Conditions studied

- Community-acquired Pneumonia
- SARS-CoV-2 -Associated Pneumonia
- Influenza With Pneumonia

## Interventions

- **DRUG:** CX-4945 (SARS-CoV-2 domain)
- **DRUG:** Placebo (SARS-CoV-2 domain)
- **DRUG:** CX-4945 (Influenza virus domain)
- **DRUG:** Placebo (Influenza virus domain)

## Key facts

- **NCT ID:** NCT06202521
- **Lead sponsor:** Senhwa Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-03-20
- **Primary completion:** 2025-04-22
- **Final completion:** 2025-04-22
- **Target enrollment:** 45 (ACTUAL)
- **Why stopped:** The trial ended early in March 2025 due to changes in disease epidemiology, affecting patient availability and recruitment feasibility.
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06202521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06202521, "CX-4945 in Viral Community Acquired Pneumonia". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06202521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*